| Autor: |
Guitti Pourdowlat, Fatemeh Saghafi, Abolfazl Mozafari, Adeleh Sahebnasagh, Atefeh Abedini, Mohsen Nabi Meybodi, Ali Salehi Nezamabadi, Seyed Ruhollah Mousavinasab, Arda Kiani, Hanieh Raji, Nadia Soltani, Mehdi Gholmzadeh Baeis, Esmaeil Eidani, Abdolrahim Sadeghi Yakhdani, Fatemeh Movaseghi, Solomon Habtemariam, Zohreh Akhoundi Meybodi, Mohsen Gholinataj Jelodar |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Phytotherapy research : PTRREFERENCES. 36(2) |
| ISSN: |
1099-1573 |
| Popis: |
Colchicine has shown clinical benefits in the management of COVID-19 via its anti-inflammatory effect. However, the exact role of colchicine in COVID-19 patients is unknown. The current clinical trial was performed on 202 patients with moderate to severe COVID-19. Patients were randomly assigned in a 1:1 ratio to receive up to a 3-day course of 0.5 mg colchicine followed by a 12-day course of 1 mg colchicine in combination with standard care or a 15-day course of standard care. Among 202 randomized patients, 153 completed the study and received colchicine/standard care or continued standard care (M age, 54.72 [SD, 15.03] years; 93 [63.1%] men). On day 14, patients in the colchicine/standard care group had significantly higher odds of a better clinical status distribution on chest CT evaluation (p = .048). Based on NYHA classification, the percentage change of dyspnea on day 14 between groups was statistically significant (p = .026), indicating a mean of 31.94% change in the intervention group when compared with 19.95% in the control group. According to this study, colchicine can improve clinical outcomes and reduce pulmonary infiltration in COVID-19 patients if contraindications and precautions are considered and it is prescribed at the right time and in appropriate cases. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text